0753 GMT April 03, 2020
The results from the Cancer Research UK-funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first-line treatment alongside hormone therapy, Science Daily wrote.
This part of the STAMPEDE trial recruited around 1,900 patients. Half the men were treated with hormone therapy while the other half received hormone therapy and abiraterone.
In men who were given abiraterone, there was a 70-percent reduction in disease progression. The drug is usually given to men with advanced prostate cancer that has spread and has stopped responding to standard to hormone therapy, but this study shows the added benefit to patients who are about to start long-term hormone therapy.
Professor Nicholas James, chief investigator of the Cancer Research UK-funded STAMPEDE trial from the University of Birmingham, said: "These are the most powerful results I've seen from a prostate cancer trial ― it's a once in a career feeling. This is one of the biggest reductions in death I've seen in any clinical trial for adult cancers.
"Abiraterone is already used to treat some men whose disease has spread but our results show many more could benefit. In addition to the improvements in survival and time without relapse, the drug reduced the rates of severe bone complications, a major problem in prostate cancer, by more than a half. I really hope these results can change clinical practice."
Alfred Samuels, 59, was diagnosed with advanced prostate cancer in January 2012 and joined the STAMPEDE trial two months later. He lives in Harrow with his wife and five children.
Alfred said: "It felt like my world fell apart overnight. The doctors explained that surgery wasn't an option for me because the cancer had spread beyond my prostate.
"But my clinician suggested that the STAMPEDE trial might be a good option. As part of the trial, I started taking abiraterone four times a day and had a hormone injection every eight weeks.
"During the first six months, tests showed that the treatment was working. I'm still on the trial, which I find reassuring and, fortunately, my cancer is being managed well."
Prostate cancer cells usually depend on testosterone to grow. Standard hormone therapy blocks the action of male sex hormones, halting the disease. Abiraterone goes further and shuts down the production of the hormones that fuel prostate cancer's growth.
Each year, around 46,500 men are diagnosed with prostate cancer in the UK, and around 11,000 men die from the disease.
Harpal Kumar, Cancer Research UK's chief executive, said: "These results could transform the treatment of prostate cancer.
Abiraterone can clearly help many more prostate cancer patients than was first thought.
"The STAMPEDE trial is changing the face of prostate cancer because the flexibility of the trial design means that we can investigate a number of different treatment options rapidly and in parallel, enabling scientists to get results much more quickly than they usually would."
Cancer Research UK scientists first discovered abiraterone and subsequently played a key role in its development, including funding the first clinical trials. This study adds to the importance of the drug.
The STAMPEDE trial is coordinated by the MRC Clinical Trials Unit at UCL and funded by Cancer Research UK.